
Novo-Nordisk A/S D
D
NVO
44.725
USD
-1.07
(-2.34%)
Market Closed
Volume
687,359
EPS
22
Div Yield
3.93
P/E
10
Market Cap
198,259,261,959







Market Roundup: What Happened Yesterday and What Awaits Us Today (February 10)








Market Roundup: What Happened Yesterday and What Awaits Us Today (February 4)


Novo Nordisk Shares Soar as FDA Clears First Weight-Loss Pill


Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies



M
R



Europe’s Biggest Companies Fall Further Behind US Rivals
Title: Novo/Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.